Monthly intravenous pulse cyclophosphamide therapy in Wegener's granulomatosis.
Clin Exp Rheumatol
; 14(1): 9-16, 1996.
Article
em En
| MEDLINE
| ID: mdl-8697666
ABSTRACT
OBJECTIVE:
To study the long term effects of monthly intravenous cyclophosphamide therapy in Wegener's granulomatosis.METHODS:
Fourteen consecutive patients with active Wegener's granulomatos treated with a first-line combination of high-dose prednisone and monthly intravenous pulse cyclophosphamide were retrospectively studied.RESULTS:
One patient died from septicemia complicating severe leukopenia after the first pulse. At 8 months after instituting intravenous pulse cyclophosphamide therapy, failure was observed in 6 other patients. Between month 16 and 18, 2 other patients relapsed when the time between 2 pulses was lengthened. Five patients developed cyclophosphamide-related side-effects infection (n = 2), amenorrhea (n = 1), alopecia (n = 2) and vomiting (n = 2). Except for one fatal infection, no major side-effect of intravenous cyclophosphamide therapy was observed. At the end of the study, all patients were off intravenous cyclophosphamide therapy with more than 6 months of followup. The 6 responders were in remission on low-dose prednisone or without treatment.CONCLUSION:
A combination of high-dose prednisone and intravenous cyclophosphamide may achieve long-term remission in 42% of patients with Wegener's granulomatosis. Responders to intravenous cyclophosphamide therapy had less extensive disease than non-responders.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Prednisona
/
Granulomatose com Poliangiite
/
Ciclofosfamida
/
Glucocorticoides
/
Imunossupressores
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Exp Rheumatol
Ano de publicação:
1996
Tipo de documento:
Article
País de afiliação:
França